alex cornell

Medicines exist for all five core drivers of mortality (statins/PCSK9 for lipids, GLP-1s for cardiometabolic, anti-amyloid for neuro, anti-inflammatories, antihypertensives) but systemic friction (complexity, cost, compliance) prevents utilization. GLP-1 commercialization proves the model: remove friction, lower cost, simplify dosing → mass adoption. Trillion-dollar annual healthcare savings achievable.

Price elasticity is extreme: compounded GLP-1s captured 15-20% market at $250/month; oral Wegovy at $150/month drives 4x launch velocity (300k vs 200k new scripts/week). Direct-to-consumer channels (Lilly Direct) now acquire >50% of new patients, bypassing physician gatekeeping. This is the first commercial proof that consumers will proactively pay for preventive medicine at scale.

Agentic AI + robotic labs compress hit-to-lead from years to months by running 24/7 in silico and physical experiments. Public literature is noisy/irreproducible; winners combine AI talent, capital, and proprietary data generation ("science tokens") to train models beyond public data limits. Scaling laws suggest deterministic path to superhuman scientific reasoning.

LDL accumulation is silent and asymptomatic until catastrophic event. PCSK9 inhibitors offer superior risk/reward vs statins (genetic evidence of safety at near-zero LDL). Compliance is the barrier: silent benefit + chronic dosing + system friction. Oral/quarterly formulations and direct access models (like GLP-1) could unlock mass preventive adoption.

Human genetic knockouts show 88% CVD risk reduction with lifelong PCSK9 deficiency; drugs achieve 50% LDL lowering and 20-25% event reduction in outcome trials. Unlike GLP-1s, minimal side effects (no nausea, muscle loss) and silent asymptomatic benefit create compliance challenge but superior risk/reward. Earlier intervention compounds benefit exponentially.

Exact Sciences (stool) and Guardant Health (blood) prove commercial viability of non-invasive colorectal screening. Blood test eliminates collection friction, driving inflection. Multi-cancer panels (50+ tumor types) advancing rapidly with AI-enhanced sensitivity/specificity. Within 5 years, routine multi-cancer blood screening could shift oncology from late-stage treatment to early interception.

Current anti-amyloid drugs (Leqembi, donanemab) clear plaques but treat too late after irreversible neurodegeneration. Biomarker-enabled early detection (blood tests coming) plus earlier dosing could 'turn off the faucet' of amyloid accumulation, potentially preventing Alzheimer's rather than slowing it. Same preventive logic validated in GLP-1 (diabetes) and PCSK9 (CVD).